PledPharma AB has together with Linköping University and Ryhov County Hospital in Jönköping received 200 000 Swedish kronor from the Research Council of the South East Sweden (FORSS) to continue clinical studies in patients with colon cancer going through cytostatic treatment.
The clinical trials test whether the PLED-derivative PP-095 reduces the frequency and severity of side effects during chemotherapy in cancer patients. Professor Ursula Falkmer at the Oncology Department at Ryhov County Hospital serves as the principal investigator in the clinical studies.
Preclinical research has shown that PP-095, a Low Molecular weight Enzyme Mimetic (LowMEM), protects normal cells and tissues without loss of anti-tumour activity during cytostatic treatment.
For further information, please contact:
Per Jynge, Medical Director, PledPharma AB, +47 735 115 55
Jan Olof G. Karlsson, Chief Scientific Officer, PledPharma AB, +46 733 304 624
PledPharma AB develops new medicines based on Low Molecular weight Enzyme Mimetics (LowMEM) with an initial candidate PP-095 for oncology. PP-095 protects against dose-limiting side effects during cancer therapy with cytostatic drugs, without diminishing the anticancer effect. PP-095 entered clinical phase II trials in cancer patients in 2008. In addition to cancer treatment, LowMEMs have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases.
For more information see www.pledpharma.se